Med 19:747-752, 2013 10. Tran E, Ahmadzadeh M, Lu YC, e t al: Immunogenicity of somati c mutations in human gastrointestinal c ancers. Science 350:1387-1390, 2015 11. Prickett TD, Crystal JS, Cohen C J, et al: Durable Complete Response from Metastatic Melanoma after Transf er of Autologous T Cells Recogn izing 10 Mutated Tumor Antigens. Cancer Immunol Res 4:669-78, 2016 12. Tran E, Turcotte S, Gros A, e t al: Cancer immunotherapy base d on mutation- specific CD4+ T cells in a patient with epithelial cancer. Science 344:641-645, 2014 13. Cohen CJ, Gartner JJ, Horovitz -Fried M, et al: Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125: 3981-91, 2015 14. Ueno H, Schmitt N, Klechevsky E, et al: Harnessing human den dritic cell subsets for medicine. Immunol Rev 234:199-212, 2010 15. Steinman RM: Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1-22, 2012 16. Mullins DW, Sheasley SL, Ream RM, et al: Route of immunizati on with peptide- pulsed dendritic cells c ontrols the distribution of memory and effector T cells in lymphoid tissues and determines the pa ttern of regional tumor control. J Exp Med 198:1023-34, 2003 17. Curti A, Tosi P, Comoli P, et al: Phase I/II clinical trial of sequential subcutaneous and intravenous deliv ery of dendritic cell vaccina tion for refractory multiple myeloma using patient-specific tumour idiot ype protein or idiot ype (VDJ)-derived class I- restricted peptides. Br J Haematol 139:415-24, 2007 18.